Quest Diagnostics Stock Hits New High Amid Apple Health Partnership and Earnings Growth
Quest Diagnostics Incorporated's stock is trading near its new high on the New York Stock Exchange, reaching around $247.96 as of September 15, 2026, up roughly 42.9 percent year-to-date according to MarketBeat.
The company's announcement that users of the Apple Health app in the United States will be able to order biomarker lab tests directly from Quest and receive results inside the app has driven investor interest in Quest Diagnostics.
This consumer-health initiative builds on Quest Diagnostics' broader strategy to grow its direct-to-consumer diagnostics business, which has been described as showing fast growth and stronger utilization alongside traditional physician and hospital channels, according to analysis cited by Quiver Quant on September 15, 2026.